Company Overview - Novanta operates in high-precision technology solutions for medical and industrial applications, focusing on innovation in photonics and motion control [6] - The company has a market capitalization of $5 billion and reported revenue of $980.6 million for the trailing twelve months (TTM) [4][11] - Novanta's net income for the TTM was $53.8 million, down from $64.1 million the previous year [11] Recent Developments - On February 17, 2026, Harvey Partners disclosed a new position in Novanta, acquiring 304,000 shares valued at $36.17 million [1][2] - This new position represents 3.21% of Harvey Partners' reportable assets under management (AUM) [8] - Novanta's stock price was $145.37 as of February 17, 2026, remaining flat over the past year, significantly underperforming the S&P 500's 16% gain [8][10] Financial Performance - Novanta's revenue increased by approximately 3% year-over-year, but operating income fell from $110.6 million in 2024 to $94 million in 2025 [11] - The company exceeded revenue expectations in the quarter and returned to organic growth, although margins suffered [11] - CEO Matthijs Glastra indicated plans to improve margins and cash flow in the current year [11] Market Position and Strategy - Novanta provides components and subsystems for photonics, vision, and precision motion, primarily serving original equipment manufacturers (OEMs) in the medical and industrial sectors [9] - The company's strategy emphasizes a diversified product portfolio and deep engineering expertise to meet complex customer needs [6] - The recent investment by Harvey Partners suggests a focus on mission-critical subsystems rather than finished products, raising questions about Novanta's ability to enhance margins and cash flow [12]